Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07708337 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating Customized Antibiotic Duration (CDA) Strategy in Acute Exacerbations of COPD

Study acronym: CDA
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Capital Development Authority (CDA)

Record History

  1. Re-verified, no change to tracked fields
  2. Primary endpoint(s) modified Start date pushed from Aug 1, 2026 to Oct 26, 2026 · Lead sponsor: Capital Development Authority (CDA) Hospital Islamabad to Capital Development Authority (CDA) · Enrollment increased: 502 → 560 participants · 5 more Show 8 more changesShow less
    • Start date pushed from Aug 1, 2026 to Oct 26, 2026
    • Lead sponsor: Capital Development Authority (CDA) Hospital Islamabad to Capital Development Authority (CDA)
    • Enrollment increased: 502 → 560 participants
    • Interventions modified
    • Eligibility criteria expanded, about 45 words
    • Secondary endpoints: 3 to 8
    • Study description shortened, about 42 words
    • Publications: details revised at 3 of 3 entries
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn whether a shorter course of antibiotics (7 days) works as well as the usual longer course (14 days) for adults admitted to hospital with a flare-up of chronic obstructive pulmonary disease (COPD), a long-term lung disease. The trial takes place at CDA Hospital Islamabad, Pakistan. The main questions it aims to answer are: * Do patients who take antibiotics for 7 days recover as well by Day 30 as patients who take them for 14 days? * Does the shorter course lead to fewer side effects and less antibiotic use, without more treatment failures, relapses or hospital readmissions? Researchers will compare a 7-day antibiotic course with the usual 14-day course to see if the shorter course is just as effective. Participants will: * Be assigned by chance (like flipping a coin) to take antibiotics for either 7 days or 14 days. Their doctor chooses which antibiotic to use. * Receive all other usual hospital care for their COPD flare-up. * Have check-ups about 3-5 days, 7 days, 14 days and 30 days after joining the trial, in hospital or by telephone, to record their symptoms, any side effects and any return to hospital. About 560 adults will take part.
Trial Details
NCT Number NCT07708337
Lead Sponsor Capital Development Authority (CDA)
Conditions COPD, Acute Exacerbation of COPD
Enrollment 560 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov